Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

133.45USD
21 Aug 2017
Change (% chg)

$0.82 (+0.62%)
Prev Close
$132.63
Open
$132.28
Day's High
$133.65
Day's Low
$132.19
Volume
4,659,993
Avg. Vol
5,550,579
52-wk High
$137.08
52-wk Low
$109.32

Select another date:
Photo

J&J ordered to pay $417 million in trial over talc cancer risks

A California jury on Monday ordered Johnson & Johnson to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.

J&J ordered to pay $417 mln in trial over talc cancer risks

A California jury on Monday ordered Johnson & Johnson to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.

UPDATE 2-J&J ordered to pay $417 mln in trial over talc cancer risks

Aug 21 A California jury on Monday ordered Johnson & Johnson to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.

J&J ordered to pay $417 mln in trial over talc cancer risks

Aug 21 Johnson & Johnson on Monday was ordered by a California jury to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

Aug 18 A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.

Judge tosses 53 plaintiffs' claims against J&J over Risperdal

Johnson & Johnson has convinced a federal judge that a recent U.S. Supreme Court ruling requires the dismissal of claims in Missouri state court by 53 out-of-state plaintiffs over injuries they blame on the antipsychotic drugs Risperdal and Invega.

BRIEF-Bavarian Nordic announces price for shares to be issued to Johnson & Johnson Innovation

* Bavarian Nordic A/S says subscription price is dkk 405.1578 per share of dkk 10

J&J loses another round in fight to toss Missouri talc cases

Johnson & Johnson has suffered another setback in its efforts to use a recent U.S. Supreme Court ruling to dismiss claims by hundreds of women and their family members in Missouri state court that its talc products can cause ovarian cancer.

Select another date: